---
title: "Obefazimod (ABX464) in Ulcerative colitis: Phase of product development"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Phase of product development. Topics: Regulatory status: Submission planned; NDA submission planned by the end of 2026; Approval timing assumed in the company's exclusivity projection: second half of 2027; Analyst assumption of U.S. market entry in 2027 (LifeSci Capital, June 2026); Development phase: phase 3 in moderately to severely active ulcerative colitis; 5 further topics. 9 evidence topics quoted from 15 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/phase-of-product-development"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Phase of product development

<a id="heading-2.1.1"></a>

## 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

### Regulatory status: Submission planned; NDA submission planned by the end of 2026

> “End of 2026 Expected Obefazimod US FDA NDA Submission”

Source: [Abivax corporate presentation (2026)](https://ir.abivax.com/static-files/ecf996c4-f156-4dac-8e1e-5c4e7cfb8e7d)

> “End of 2026 – Planned NDA submission for obefazimod in UC”

Source: [Abivax first half 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-business-updates-and-first-half-2026-financial)

> “Constructive FDA feedback resulted in alignment on the Company's planned NDA submission strategy and supported the planned content and format of the NDA submission. Abivax remains on track to submit its first NDA for obefazimod by the end of 2026.”

Source: [Abivax press release, pre-NDA interaction with the FDA (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-pre-nda-interaction-fda-obefazimod)

> “These additions strengthen Abivax's commercial organization as the Company prepares for the potential U.S. commercialization of obefazimod, including a planned New Drug Application”
> “in the fourth quarter of 2026.”

Source: [Abivax press release, commercial leadership appointments (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-strengthens-commercial-capabilities-strategic-leadership)

> “The Company remains on track to submit its NDA to the U.S. Food and Drug Administration in the fourth quarter of 2026.”

Source: [Abivax press release, ABTECT maintenance Part 2 results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results)

> “Abivax intends to submit an NDA to the FDA in late fourth quarter 2026.”

Source: [Abivax press release, ABTECT maintenance results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-landmark-phase-3-abtect-maintenance-trial)

<a id="topic-2.1.1-2"></a>

### Launch

No evidence found.

<a id="topic-2.1.1-3"></a>

### Approval timing assumed in the company's exclusivity projection: second half of 2027

> “If obefazimod is approved by the FDA in 2H 2027, the FDA will grant an additional 7.5 years of exclusivity for a newly approved chemical entity (5 years of regulatory exclusivity plus 2.5 years of litigation stay against generic(s)), taking obefazimod’s US exclusivity, at a minimum, through 2034.”
> “If obefazimod is granted market authorization by the EMA in 2028, 8 years of data exclusivity + 2 additional years of market exclusivity would be granted”

Source: [Abivax corporate presentation (2026)](https://ir.abivax.com/static-files/ecf996c4-f156-4dac-8e1e-5c4e7cfb8e7d)

<a id="topic-2.1.1-4"></a>

### Analyst assumption of U.S. market entry in 2027 (LifeSci Capital, June 2026)

> “obefazimod enters the market for moderate to severe ulcerative colitis in 2027”

Source: [Streetwise Reports (2026)](https://www.streetwisereports.com/article/2026/07/01/clinical-stage-biotech-discloses-colitis-retreatment-results-gets-mixed-ratings.html)

<a id="topic-2.1.1-5"></a>

### Development phase: phase 3 in moderately to severely active ulcerative colitis

> “Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.”

Source: [Abivax first half 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-business-updates-and-first-half-2026-financial)

> “Maintenance trial topline data readout Part 1 & 2 in June 2026”

Source: [Abivax corporate presentation (2026)](https://ir.abivax.com/static-files/ecf996c4-f156-4dac-8e1e-5c4e7cfb8e7d)

<a id="topic-2.1.1-6"></a>

### Authorization status: not approved in any jurisdiction

> “It has not yet been approved for commercial use in any jurisdiction.”

Source: [Abivax obefazimod web page](https://www.abivax.com/our-science/obefazimod/)

> “The product is not authorised anywhere in the European Community.”

Source: [EMA paediatric investigation plan decision, March 2025 (2025)](https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000189672-ema-decision-20-march-2025-acceptance-modification-agreed-paediatric-investigation-plan-obefazimod_en.pdf)

<a id="topic-2.1.1-7"></a>

### NDA submission timing: company guidance from January 2026 to May 2026

> “NDA submission for obefazimod in UC - Q4 2026 (subject to positive data)”

Source: [Abivax first quarter 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-first-quarter-2026-financial-results-and-reports)

> “Subject to positive data, we currently expect to submit our NDA with the FDA in the fourth quarter of 2026.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

> “NDA submission for obefazimod in UC - Q4 2026 (subject to positive data)”

Source: [Abivax full year 2025 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-full-year-2025-financial-results-and-provides)

> “Ongoing New Drug Application (NDA) preparation includes planned engagement with the FDA in anticipation of planned filing in late 2026.”

Source: [Abivax press release, 2026 corporate outlook (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-provides-2026-corporate-outlook)

<a id="topic-2.1.1-8"></a>

### Marketing authorization application to the EMA: planned for the second half of 2026, July 2025 statement

> “Regulatory Strategy: Contingent on positive 44-week maintenance results, Abivax intends to submit a New Drug Application”
> “to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application”
> “to the European Medicines Agency (EMA) in the second half of 2026.”

Source: [Abivax press release, ABTECT induction results (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-phase-3-results-both-abtect-8-week)

<a id="topic-2.1.1-9"></a>

### EU paediatric investigation plan for ulcerative colitis: modification accepted in March 2025

| Field | Quoted record |
| --- | --- |
| Decision | “EMA/PE/0000189672” |
| Decision date | “of 20 March 2025” |
| Condition | “Treatment of ulcerative colitis” |
| Indication targeted by the PIP | “Treatment of patients diagnosed with moderately to severely active ulcerative colitis (UC)” |
| Paediatric subset concerned | “From 2 years to less than 18 years of age” |
| Waiver | “the paediatric population from birth to less than 2 years of age;” |
| Paediatric clinical study | “2-part, multi-centre, double-blind induction and maintenance study to evaluate the efficacy, safety, tolerability and PK of obefazimod in paediatric patients with moderately to severely active ulcerative colitis aged from 2 years to less than 18 years.” |
| Date of completion of the PIP | “By June 2029” |
| Deferral | “Yes” |

Source: [EMA paediatric investigation plan decision, March 2025 (2025)](https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000189672-ema-decision-20-march-2025-acceptance-modification-agreed-paediatric-investigation-plan-obefazimod_en.pdf)

<a id="topic-2.1.1-10"></a>

### EU paediatric investigation plan: modification accepted in June 2024

> “European Medicines Agency decision P/0205/2024 of 14 June 2024”
> “Having regard to the European Medicines Agency’s decision P/0519/2022 issued on 30 December 2022,”
> “Amendment of the scope of the Paediatric Investigation Plan to exclude another condition.”

Source: [EMA paediatric investigation plan decision P/0205/2024 (2024)](https://www.ema.europa.eu/en/documents/pip-decision/p-0205-2024-ema-decision-14-june-2024-acceptance-modification-agreed-paediatric-investigation-plan-obefazimod-emea-003196-pip01-22-m01_en.pdf)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
